Literature DB >> 2597314

The apparent autoxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra.

B Fornstedt1, A Brun, E Rosengren, A Carlsson.   

Abstract

The concentrations of the 5-S-cysteinyl adducts of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and 3,4-dihydroxyphenylalanine (DOPA) and the levels of noradrenaline (NA), DA, DOPAC and DOPA were determined in the putamen (PUT), caudate nucleus (CN) and substantia nigra (SN) of human post mortem brains with or without depigmentation and degeneration of the SN. The levels of DA, DOPAC and DOPA decreased with the degree of depigmentation and degeneration in the three brain regions while NA levels only decreased in SN and PUT. In general, the concentrations of the 5-S-cysteinyl adducts did not differ, but the ratios of 5-S-cysteinyl-DA/DA, 5-S-cysteinyl-DOPAC/DOPAC and 5-S-cysteinyl-DOPA/DOPA were higher in patients with a more depigmentated and degenerated SN, except for the 5-S-cysteinyl-DA/DA ratio in the PUT. Higher ratios were also found in the cell body areas compared to the neuron terminal areas. Thus depigmentation and degeneration of dopaminergic SN neurons, seem to be correlated to enhanced rates of autoxidation, possibly due to an impaired antioxidant capacity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2597314     DOI: 10.1007/bf02263482

Source DB:  PubMed          Journal:  J Neural Transm Park Dis Dement Sect        ISSN: 0936-3076


  29 in total

1.  Neurotoxicological and neuroprotective elements in Parkinson's disease.

Authors:  Richard M. Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

2.  The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface.

Authors:  William D Bush; Jacob Garguilo; Fabio A Zucca; Alberto Albertini; Luigi Zecca; Glenn S Edwards; Robert J Nemanich; John D Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-25       Impact factor: 11.205

3.  Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.

Authors:  P M Carvey; S Pieri; Z D Ling
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Disruption of dopamine transport by DDT and its metabolites.

Authors:  Jaime M Hatcher; Kristin C Delea; Jason R Richardson; Kurt D Pennell; Gary W Miller
Journal:  Neurotoxicology       Date:  2008-04-29       Impact factor: 4.294

5.  Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.

Authors:  F C Cheng; J S Kuo; L G Chia; G Dryhurst
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

6.  Model neuromelanins as antioxidative agents during lipid peroxidation.

Authors:  T Wilczok; K Stepien; A Dzierzega-Lecznar; A Zajdel; A Wilczok
Journal:  Neurotox Res       Date:  1999-12       Impact factor: 3.911

7.  Neurotoxicity due to o-quinones: neuromelanin formation and possible mechanisms for o-quinone detoxification.

Authors:  F Solano; V J Hearing; J C García-Borrón
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

8.  Intraneuronal dopamine-quinone synthesis: a review.

Authors:  D Sulzer; L Zecca
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

9.  Substrate specificity of human glutamine transaminase K as an aminotransferase and as a cysteine S-conjugate beta-lyase.

Authors:  Arthur J L Cooper; John T Pinto; Boris F Krasnikov; Zoya V Niatsetskaya; Qian Han; Jianyong Li; David Vauzour; Jeremy P E Spencer
Journal:  Arch Biochem Biophys       Date:  2008-02-29       Impact factor: 4.013

Review 10.  The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse.

Authors:  Bryan K Yamamoto; Jamie Raudensky
Journal:  J Neuroimmune Pharmacol       Date:  2008-08-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.